摘要
目的比较英夫利昔单抗和美沙拉嗪用于治疗溃疡性结肠炎的临床疗效。方法选取2017年3月至2019年2月本院收治的98例溃疡性结肠炎患者为研究对象,按照治疗方案分为探究组和参照组,每组49例。探究组患者采用英夫利昔单抗药物治疗,参照组患者采用美沙拉嗪药物进行治疗,比较两组患者临床疗效。结果探究组患者治疗总有效率高于参照组,组间差异具有统计学意义(P<0.05);探究组患者便血和腹痛缓解时间短于参照组,组间差异具有统计学意义(P<0.05);探究组患者用药后不良反应发生率显著低于参照组,组间差异具有统计学意义(P<0.05)。结论与美沙拉嗪比较,采用英夫利昔单抗治疗溃疡性结肠炎的临床疗效和安全性更高,值得临床应用推广。
Objective To compare the clinical efficacy of infliximab and mesalazine in the treatment of ulcerative colitis.Methods A total of 98 patients with ulcerative colitis who were admitted to our hospital from March 2017 to February 2019 were enrolled,the patients were divided into inquiry group and reference group according to the medication regimen,with 49 cases in each group.Patients in the inquiry group were treated with infliximab,and patients in the reference group were treated with mesalazine.The clinical efficacy of the two groups was compared.Results The total effective rate of treatment in the inquiry group were higher than those in the reference group,and the difference between the groups was significant(P<0.05).The time to relieve blood in the stool and abdominal pain in the inquiry group were shorter than the patients in the reference group,and the difference between the groups was significant(P<0.05).The incidence of adverse reactions in the inquiry group was significantly lower than that in the conventional group,and the difference between the two groups was significant(P<0.05).Conclusion Compared with mesalazine,infliximab is more effective and safer in the treatment of ulcerative colitis,it is recommended to be used in clinical promotion.
作者
宫宁宁
王西艳
胡克伟
Gong Ningning;Wang Xiyan;Hu Kewei(Department of Spleen and Stomach Diseases,Weifang Traditional Chinese Hospital,Weifang,Shandong,261000,China;Department of Gastroenterology,Center Hospital of Rizhao,Rizhao,Shandong,276800,China;Department of Bone Injury Rehabilitation,Weifang Traditional Chinese Hospital,Weifang,Shandong,261000,China)
出处
《当代医学》
2020年第11期10-12,共3页
Contemporary Medicine
